TLSA

Tiziana Life Sciences Ltd

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.14
52-Week Range: $0.76 – $2.33
Market Cap: $142.53M
P/E (TTM): —
EPS (TTM): -0.16
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -924.32%
Return on Assets: -115.96%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.76
Debt/Equity: 8.77
Total Debt: $456.00K
Free Cash Flow: $-5.48M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $131.41M

TLSA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$12.96M	$8.11M	$5.23M	$10.28M
Selling, General & Admin	$0.00	$0.00	—	—
Operating Expenses	$14.59M	$17.98M	$15.79M	$21.13M
Operating Income	-$14.59M	-$17.98M	-$15.79M	-$21.13M
EBITDA	-$15.31M	-$17.14M	-$16.62M	-$18.18M
Pretax Income	-$15.40M	-$17.24M	-$16.75M	-$18.43M
Income Tax	$0.00	$449.00K	-$4.88M	$0.00
Net Income	-$15.40M	-$17.69M	-$11.86M	-$18.43M
Diluted EPS	-0.15	-0.17	-0.11	-0.16
Diluted Shares	101.53M	102.47M	106.67M	118.28M

TLSA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.12M	$1.18M	$3.72M	$4.01M
Receivables	$5.99M	$6.05M	$3.69M	$4.26M
Current Assets	$24.28M	$7.34M	$7.51M	$8.55M
Total Assets	$26.48M	$12.18M	$11.28M	$11.49M
Current Liabilities	$6.66M	$6.54M	$7.35M	$11.21M
Total Debt	$365.00K	$247.00K	$106.00K	$456.00K
Total Liabilities	$6.91M	$6.65M	$7.35M	$11.44M
Retained Earnings	-$116.26M	-$133.68M	-$144.83M	-$163.11M
Shareholders' Equity	$19.57M	$5.54M	$3.94M	$52.00K
Working Capital	$17.62M	$798.00K	$160.00K	-$2.66M

TLSA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$19.61M	-$15.70M	-$1.53M	-$12.85M
Capital Expenditure	—	—	-$19.00K	-$21.00K
Free Cash Flow	-$19.61M	-$15.70M	-$1.54M	-$12.87M
Depreciation & Amortisation	$51.00K	$96.00K	$124.00K	$234.00K
Stock-Based Compensation	-$1.41M	$1.73M	$1.43M	$1.14M
Investing Cash Flow	-$4.00M	-$1.25M	-$71.00K	$3.04M
Financing Cash Flow	-$55.00K	$40.00K	$4.50M	$10.01M
Net Change in Cash	-$23.67M	-$16.91M	$2.91M	$202.00K

TLSA Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q2 2025	Q4 2025
Cash & Equivalents	$3.72M	—	$4.01M
Receivables	$3.69M	—	$4.26M
Current Assets	$7.51M	—	$8.55M
Total Assets	$11.28M	—	$11.49M
Current Liabilities	$7.35M	—	$11.21M
Total Debt	$106.00K	—	$456.00K
Total Liabilities	$7.35M	—	$11.44M
Retained Earnings	-$144.83M	—	-$163.11M
Shareholders' Equity	$3.94M	—	$52.00K
Working Capital	$160.00K	—	-$2.66M

Market Snapshot

About

Tiziana Life Sciences Ltd is a biotechnology company focused on discovering and developing transformative therapies for cancer and immune-modulated inflammatory diseases. The company is advancing novel intranasal immunotherapies and other innovative treatments.